The researchers used the most advanced genomic and proteomic technologies available to tease out their proteogenomic characteristics, defined as genetic makeup (genomics), chemical modifications to DNA (epigenomics), messenger RNA located in cells that serves as template to make proteins (transcriptomics), and proteins (proteomics) and their modification by phosphate group (phosphoproteomics), a modification known to regulate protein functions by switching on or off. The work was completed as a national effort to better understand cancers through proteogenomics.
Among their findings, investigators say, was that the loss of chromosome 3p is an apparent hallmark of ccRCC, occurring in almost all of the tumor samples in the study.
In addition, the researchers identified four distinct immune-based subtypes of ccRCC based on their immune cell differences that potentially could be used to help predict patients' overall survival and response to treatment.
Among all kidney cancers, ccRCC accounts for 75%, equating to about 65,000 new cases annually. Surgical removal remains the only effective treatment for cancers that have not spread beyond the kidney, but 30% of patients present with advanced disease at diagnosis.
"Historically, ccRCC has been considered resistant to conventional chemotherapy and radiation, and response to several FDA-approved drugs has been limited," says the senior author. "Our results illustrate the complexity of cancer development, and that we can use proteomics and phosphoproteomics in addition to genomics to learn more about cancer phenotypes and their heterogeneity," says the co-principal investigator of the study..
"The use of one type of molecular study to understand cancer is no longer enough. A multi-omic approach is needed to fully characterize cancer," says lead study author. Currently, the lead adds, frontline treatment for ccRCC that cannot be cured surgically is focused on inhibiting angiogenesis, the process by which cancers develop new blood vessels to maintain nourishment and growth, and targeting a protein kinase called mTOR that helps control cell survival and division. Overlaying the proteomic and phosphoproteomic data makes it possible, for researchers to detect a wider array of potential targets for new drug development.
Other key findings of the analysis found that:
There were four distinct subtypes of ccRCC based on their tumor microenvironment signatures:
CD8-positive inflamed tumors had a high amount of CD8-positive immune cells and responded to cell signaling pathways associated with an immune response.
CD8-negative inflamed tumors had a near absence of CD8-positive immune cells but did have cells such as fibroblasts, which promote wound healing, and macrophages, which fight cancers and other foreign substances.
Vascular endothelial growth factor (VEGF) immune desert tumors had no immune cells but had a strong presence of endothelial cells associated with the development of new blood vessel growth in tumor progression.
Metabolic immune desert cells were more pure tumor cells with almost no immune cells and very few fibroblasts.
Based on The Cancer Genome Atlas datait appeared that those with CD8-positive inflamed tumors would have a worse overall survival while those with VEGF immune desert tumors would have the best overall survival. New predictive models by the researchers found that those with CD8-positive tumors would have the best response to immune checkpoint therapies, whereas those with VEGF immune desert tumors would show the best response to anti-angiogenesis therapies, targeted treatments that cut tumors off from their blood supply.
The team next plans to use similar methods to more fully characterize pancreatic and head and neck cancers.